Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.

Cancer science - 1 Sept 2020

Sekiguchi Naohiro, Rai Shinya, Munakata Wataru, Suzuki Kenshi, Handa Hiroshi, Shibayama Hirohiko, Endo Tomoyuki, Terui Yasuhito, Iwaki Noriko, Fukuhara Noriko, Tatetsu Hiro, Iida Shinsuke, Ishikawa Takayuki, Shiibashi Ryota, Izutsu Koji

Abstract excerpt

Tirabrutinib is a second-generation Bruton's tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström's macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Differentiation Factor 88

Share to Neoplasm Grading

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Receptors, CXCR4

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed Open full text

Identifiers

PMID: 32639651
DOI: 10.1111/cas.14561
PMCID: PMC7469793

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.PMID 32639651Read ↗

Ibrutinib in previously treated Waldenström's macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.Semantic proximity Read ↗

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.Semantic proximity Read ↗

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.Semantic proximity Read ↗

First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.Semantic proximity Read ↗

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.Semantic proximity Read ↗

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Emerging drugs for the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Current approach to Waldenström Macroglobulinemia.Semantic proximity Read ↗

[Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].Semantic proximity Read ↗

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.